Best GLP-1 Provider If You Have Thyroid Issues

If you've been diagnosed with a thyroid condition, the boxed warning on every GLP-1 medication has probably caught your eye. It references thyroid C-cell tumors found in rodent studies and warns against use in patients with medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

But that warning is narrower than most people realize. Understanding exactly what it does and doesn't cover is the first step toward safely accessing GLP-1 treatment.

Hard Contraindication GLP-1 medications are contraindicated — meaning you should not take them — if you have a personal or family history of medullary thyroid carcinoma (MTC) or a diagnosis of Multiple Endocrine Neoplasia type 2 (MEN2). This applies to all GLP-1 receptor agonists, including semaglutide, tirzepatide, and liraglutide. No provider should prescribe a GLP-1 if you have either condition.

What the FDA Warning Actually Covers

The FDA boxed warning originates from rodent studies where animals developed C-cell hyperplasia and tumors when exposed to GLP-1 drugs at high doses over extended periods. However, important biological differences exist between rodents and humans. Human thyroid C-cells express substantially lower levels of GLP-1 receptors compared to rodents.

A 2026 white paper from the Clayman Thyroid Center — one of the highest-volume thyroid cancer centers in the world, treating approximately 2,000 thyroid cancer patients annually — found no convincing evidence linking GLP-1 medications to common thyroid cancers. The center's surgeons reported they have not observed a pattern linking GLP-1 use to medullary thyroid carcinoma in their clinical practice.

The key distinction: medullary thyroid carcinoma accounts for only 3–4% of all thyroid cancer cases. The far more common papillary, follicular, and Hürthle cell thyroid cancers are not contraindicated for GLP-1 use. Having thyroid nodules is also not a contraindication.

Bottom Line Hypothyroidism and hyperthyroidism are not contraindications for GLP-1 medication. Only medullary thyroid carcinoma and MEN2 prevent GLP-1 use. If you take levothyroxine for hypothyroidism, your provider may want to monitor thyroid levels more frequently during the early months of treatment, especially if you're using oral semaglutide (which can affect medication absorption timing).

What to Look for in a Provider

If you have a thyroid condition, you want a provider whose intake process asks about thyroid history specifically — not just a generic health questionnaire that glosses over it. You also want a provider willing to coordinate with your endocrinologist or primary care doctor on monitoring.

Here's what separates adequate from excellent in this context:

Detailed intake screening: The intake should specifically ask about thyroid cancer type, family history of MTC, MEN2 status, and current thyroid medications.
Lab work protocols: Providers who require or recommend baseline lab work can catch thyroid function changes early. Look for programs that monitor TSH at minimum.
Provider access: If you're on levothyroxine, you may need dose adjustments as your weight changes on GLP-1. Choose a provider that offers real follow-up, not just a prescription.
Brand-name option: Brand-name medications come with established dosing data and FDA-approved labeling that your endocrinologist can reference. Some patients with thyroid conditions prefer this certainty.

Our Picks for Patients With Thyroid Conditions

Sesame Care

Brand-name only · Direct prescriber access

Sesame connects you with licensed prescribers who can write for FDA-approved brand-name GLP-1 medications like Wegovy, Zepbound, or Rybelsus. Because they work with brand-name products exclusively, the dosing and safety data are fully established — which matters when you're coordinating with an endocrinologist.

See Sesame Options →

Paid link

MEDVi

24/7 provider access · Oral + injectable options

MEDVi offers 24/7 provider messaging, which is valuable if you're on levothyroxine and need to discuss timing adjustments or symptom changes between scheduled visits. Their intake process screens for thyroid conditions. They offer both injectable and oral compounded options.

⚠️ Note: MEDVi received an FDA warning letter in February 2026 regarding product labeling. We continue to monitor their compliance status.

Start MEDVi Intake →

Paid link · Compounded medications are not FDA-approved.

Care Bare Rx

Dedicated intake flow · Affordable starting price

Care Bare Rx uses a structured intake process and routes patients through a provider review before prescribing. Their program starts from $199/month with no long-term contract required. Good option if you want a thorough screening process at a moderate price point.

Check Care Bare Pricing →

Paid link · Compounded medications are not FDA-approved.

Questions to Ask Your Provider

Before starting any GLP-1 program, ask your prescribing provider these questions if you have a thyroid condition:

What type of thyroid condition do I have, and does it fall under the FDA's contraindication? (If you don't know your specific thyroid cancer subtype, get clarification before proceeding.)
Should my TSH and thyroid hormone levels be checked before starting, and how often should they be monitored?
If I take levothyroxine, will GLP-1 medication — particularly oral formulations — affect my absorption?
Are you willing to communicate with my endocrinologist if needed?

Any provider who dismisses these questions or tells you thyroid conditions don't matter at all is not one you should trust with your care.

Compare Providers by Safety Features

See which providers offer lab work, real doctor access, and thorough intake screening.

View Full Comparison →